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Studies ofT cell-mediated immune response against spontaneously arising au-
tologous human tumors have been markedly facilitated by functional analyses of
T cells at the clonal level (1-7). This particular approach has now provided a strong
support forthe long-heldbeliefby some, althoughviewed skeptically by others, that
T cell-mediatedhost responses do indeed exist in different types ofhuman cancers.
The evidence for such T cell antitumor response has been particularly impressive
in malignant melanoma (1-4, 6, 7). In this system, the existence ofCTL response
(1-4, 6, 7), proliferative Tcell response (8, 9), suggestion for regulatory T cell re-
sponse (10, 11), anddelayed-type hypersensitivity response(12)have allbeendemon-
strated. While this impressive body ofevidence certainly represents aserious begin-
ning in investigation onTcell responses against autologous cancer, acritical analysis
ofTcell-immuneresponses against alarge numberofautologous melanomaatclonal
levels is necessary for a more comprehensive understanding ofT cell-immune re-
sponse inhost defenseagainst human cancersor, forthat matter, against malignant
melanoma.
We have undertaken clonal analyses ofT cell-immune response in a larger group
ofpatients with melanoma. Inthis work, we present our observation ofclonal anal-
yses ofCTL and regulatory responses in 31 autologous case studies. Here we show
that T cell responses (CTL as well as regulatory T cell responses), taken together,
are demonstrable in approximately half of this cohort of subjects. Results of our
studies clearly document the involvement ofthe entire T cell repertoire in response
to autologous melanoma. The melanoma-specific (CTL) responses show appropriate
MHC class restriction, and the cytotoxic response in the PBL is subject to regula-
tion by the helper and suppressor arms of the T cell network. The amplification
ofcytotoxic response by Th cell clones is mediated by the elaboration of IL-2 and
IFN-y, and the T cell-mediated downregulatory responses can be specific as well
as nonspecific.
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Materials and Methods
Patients.
￿
All31 patients had recurrent and/or advanced metastatic disease. Specimens (tissue
or blood) were obtained with informed consent.
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Tumor Cells.
￿
We performed all experiments with melanoma cell lines established in our
laboratory (from 20 of these 31 cases) or with freshly isolated tumor cells from melanoma
explants (11 :31 cases). The procedure of isolating fresh cells from tissue explants has been
described earlier (13). Cells were cryopreserved (-180°C) in filtered FCS with 10% DMSO
in multiple aliquots. Quickly thawed cells were 90% viable by trypan blue dye exclusion test.
By cytologic and morphologic criteria, the single cells were 95% monomorphic, consistent
with the cytology ofmelanoma cells, and expressed one or more ofthe three antigens charac-
teristically expressed by melanoma cells (D/DR antigen and ganglioside antigens GD3 and
GM2) when tested by immunofluorescense tests with mAb anti-D/DR framework 12 (Coulter
Electronics Inc., Hialeah, FL), mAb anti-GD3 R24 (a gift of Alan Houghton, Memorial
Sloan-Kettering Cancer Center, New York, NY), and mAb anti-GM2 (a gift ofPhilip Living-
ston, Memorial Sloan-Kettering Cancer Center) .
Lymphocytes.
￿
PBL were isolated on a Ficoll-Hypaque gradient fresh for each experiment.
Further, autologous lymph node-derived lymphocytes (LNL)' were also isolated by a tech-
nique described earlier (10) on a Ficoll-Hypaque gradient from a single cell preparation of
lymph nodes that were partially infiltrated with melanoma cells. All cultures and every ex-
periment were initially performed in Ham's F-10 medium and, subsequently, in Iscoves medium
(Gibco Laboratories, Grand Island, NY) containing 10'7o FCS.
In Vitro Coculture (IVC).
￿
The basic IVC technique has been described previously (10). Briefly,
effector cells (106/ml) were cocultured with irradiated (3,000 rad) autologous or allogenic
targets (104/ml) in medium supplemented with 10% FCS. Depending on experimental pro-
tocol, 64 U of lectin-free and purified IL-2 (Electronucleonics, Silver Spring, MD) was added
to the cultures on day 3 of the cultures or cocultures. Unless mentioned otherwise, the stan-
dard in vitro activation coculture protocol for activation of cytotoxicity consisted of a cocul-
ture of effector cells and target cells in medium containing IL-2 (64 U/ml) from day 3 fol-
lowed by cytotoxicity assay on day 7 .
Lymphocyte Cloning.
￿
Lymphocytes were cloned by the limiting dilution microculture tech-
nique as described earlier (1), with minor modifications. To generate clones, irradiated (3,000
rad), autologous PBL (alone or with allogeneic PBL from one or two healthy donors) were
used as feeder cells at concentrations of 104 cells/well. 10-20 96-well U-bottomed cluster plates
(Costar, Cambridge, MA) were seeded with the sensitized B lymphocytes or LNL at concen-
trations such that one ofthree wells, or each well, would have received a single cell. Microwells
were fed with a drop of64 U/ml ofIL-2-containing medium every other day. Visible colonies
were removed to another 96-well plate and were longitudinally expanded by dividing the con-
tents of one well into two wells. The contents of six to eight wells were subsequently pooled
into 48-well and, then, into 12-well cluster plates. Bulk cultures (0.5-1.0 x 106 cloned cells)
were restimulated with autologous melanoma cells (100 Ly-1 melanoma cells) with or without
autologous lymphoid cells (cloned cell(s)/accessory lymphoid cell = 2:1). The stimulatory
cells were irradiated (3,000 rad).
Phenotypic Analysis.
￿
Procedures for phenotypic analysis in FAGS has been previously de-
scribed (1). mAb Tac was a gift of Thomas Waldman (National Institutes of Health, Bethesda,
MD). mAb W632 was a gift of Soldano Ferrone (New York Medical College, Valhalla, NY).
Anti-CD2, -CD3, -CD4, and -CD8 reagents were purchased form Ortho Diagnostic Systems
Inc., Westwood, MA. Anti-D/DR mAb 12 was purchased from Coulter Electronics Inc.
In Vitro Microcytotoxicity (Cell-mediated Cytotoxicity) Assay.
￿
The 5'Cr release microcytotox-
icity assay has been described earlier (1). Cultured target cells, freshly prepared targets, and
the cryopreserved targets were labeled with "Cr with good eficiency, the mean spontaneous
release of "Cr from 20 separate experiments was 11.5% (range, 4-19%). For the purpose of
quantitative comparison, the cytotoxic ability of a given activated PBL population was ex-
pressed as LU (111,000)/106 BMN. 1 LU equals the number of lymphocytes required to lyse
1,000 target cells (i.e., 50% lysis of 2,000 target cells/well). The standard cold target competi-
tion assay for analysis of specificity of cytotoxicity has been described earlier (14) .
' Abbreviations used in this paper: AMLR, autologous mixed leukocyte reaction; ICAM, intercellular
adhesion molecule; IVC, in vitro coculture; LFA, lymphocyte function-associated antigen; LNL, lymph
node-derived lymphocytes.AssayforRegulation ofCytotoxicity.
￿
The basic in vitro assay to examine cell-mediated regu-
lation of cytotoxic response in in vitrococulture has been published earlier (10, 11, 13). Briefly,
to assay regulation of generation of cytotoxicity in the PBL (at induction phase), standard
in vitro activation cocultures between PBL and irradiated targets (3,000 rad) were set up
in the presence or in the absence of irradiated (3,000 rad) cloned lymphocytes as potential
regulatory cells at different PBL to regulatory cell ratios. Cytotoxicity was assayed on day
7 at different E/T ratios. Percent enhancement and percent suppression were calculated with
the following formulas: percent suppression = 100 x [1 - (percent specific lysis with regula-
tory cells)/(percent specific lysis without regulatory cells)]; percent enhancement = 100 x
[1 - (percent specific lysis without regulatory cells)/(percent specific lysis with regulatory
cells)] . Mean cpm of three replicate samples from wells containing the E/T ratio of 20 :1 was
used to calculate percent changes. To assay potential regulation ofcytotoxicity at the effector
phase, cytotoxiciy of the CTL clones was assayed in the presence or absence of autologous
sera or of PBL as potential regulatory cells.
Results
Cytotoxic Response Against Autologous Target Cells.
￿
Fig. 1 shows representative ex-
amples ofcytolytic responses by the freshly derived and in vitro activated autologous
PBL or LNL in three autologous melanoma systems. In none ofthesethree systems
were the fresh PBL or LNL cytotoxic against the respective autologous targets. In
two cases, the activated effectors, however, exhibited significant levels of cytotoxicity
against the autologous targets. In a composite analysis of 31 autologous systems,
the freshly derived PBL or LNL were marginally cytotoxic against the autologous
targets in only two cases. In 19 of 31 cases, the activated effector cells (PBL, LNL,
or both) exhibited significant cytotoxicity (> ,10 LU 1,000/106 effector cells) (combined
data not shown). In continuous culture the cytotoxic responses by the effector cells
usually reached their peak levels by 2-3 wk and declined to the base line levels by
the 5th to 7th week (data not shown). Restimulation with autologous melanoma cells
as antigen and PBL or spleen cells (whenever available) as accessory cells helped
the cytotoxic activity to rebound somewhat, but seldom to their earlier peak levels
(datanot shown). Although differences in the cytotoxic response (ranging from minor
to marked) between autologous PBL and LNL was observed in several cases, cyto-
toxic unresponsiveness did not reside exclusively, however, with the PBL or with the
LNL (composite data not shown).
The cytotoxic responses by the activated PBL or LNL were almost always seen
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FIGURE 1.
￿
Cytotoxicity by the fresh
PBL(O)andby theactivated PBL(0)
against the corresponding autologous
melanoma cells. Cytotoxicities of the
activated PBLwere tested at 2 wkafter
the initiation of IVC.1964 CYTOTOXIC AND REGULATORY T CELL RESPONSES IN MELANOMA
against a broad range of target cells, including the NK-sensitive target, K-562 . The
activated PBL or LNL usually contained both CD4+ and CD8+ populations, al-
though insome cases therewas asignificantpreponderanceofone subset or another.
For example, in the DM system (Fig . 1), the activated PBL were predominantly
CD4+ (80%); whereas, in the PT system, they were predominantly CD8 + (90%) .
Fig. 2 shows the cytotoxic profiles of threeCD8+ clones in the PT system . In this
system, clone A15 demonstrated abroad range of cytotoxic activity ; while clone PT
32 was noncytotoxic. Clone PT 31, on the other hand, exhibited cytotoxicity that
was restricted against the autologous target PTIM . All three clones were phenotypi-
cally identical (CD3 + , CD8+, CD4-, Ia+), and the two cytotoxic clones (PT 31 and
A15) required periodic (every 1-2 wk) stimulation with the autologous melanoma
cells PTIM with or without autologous PBL or splenocytes (irradiated to 3,000 rad)
formaintenence of theircytotoxic functions . Unstimulated cultures rapidly lost cyto-
toxic function .
Fig. 3 shows the cytotoxic profiles of four CTL clones that were derived from acti-
vatedPBL or LNL from four separate cases . Clone PT 31 and RN C8 were derived
from activated PBL; whereas, the other two clones were derived from activated LNL
from melanoma-involved lymph nodes . All four clones expressed identical pheno-
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Cytotoxic profiles ofthree
clones against the autologous mela-
noma cellsPTM. Percent specific lysis
represented by the solid bars wasat E/T
ratio = 20:1 andwasE/T ratio = 10 :1
as represented bythe broken bars . PT
M,TRM, FP-M, andCLB-M, mela-
noma cells ; K-562 erythroleukemia cell
line; and M-OV, ovarian cancer cells .
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FIGURE 4.
￿
Cold target inhibi-
tion assays with CTL clones
Tc1.8 (in the VIP system) and
PT 31 (in the PT system). (A)
Clone Tc1.8 was tested against
labeled autologous melanoma
cells VIP (at effector/labeled
VIP target of 10:1) in the pres-
ence of unlabeled VIP ("), of
unlabeled K-562 (O), of unla-
beled Daudi cells (A), of unla-
beled PJ-M cells (/), and of
unlabeled MOLT 4 cells (*).
(B) Clone PT 31 was tested
against labeled autologous mel-
anoma cells PTIM (at effector/
labeled PTM target of20:1) in
the presence of unlabeled PT-
M cells (0), of unlabeled FP
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type (CD3+, CD8+, CD4-, WT31+, and HNKI-), and all lysed the respective au-
tologous melanoma cells in a restricted fashion. The CTL clone RN C8 could not
be maintained in continuous culture long enough to perform more detailed anal-
yses. The other three clones grew for a long enough time to allow more detailed
analyses. The restricted specificities for the respective autologous melanoma cells
were confirmed in cold target competition assays in two systems. In both systems,
only the autologous melanoma cells avidly competed withthe correspondinglabeled
autologous melanoma cells for the corresponding CTL receptors (Fig. 4). Three
CTL clones (clone Tcl.8inthe VIP system, clone PT 31 in the PT system, and clone
MCC5 in the MC system) demonstrated MHC class I-restricted killing, whileclone
RN C8 in the RN system showed no MHC restriction (Table I).
To analyze the broad target range ofthe cytotoxic behavior of clone A15 in the
PT system, we carried out its specificity analysis in cold target competition assay.
Interestingly, in cytotoxic interaction between clone A15 and the autologous PTIM
TABLE I
Effect of Anti-MHC Antibody on Cytotoxicity by CTL Clones
Percent specific lysis at E/T ratio is 20:1 .
' When compared with percent specific lysis by the corresponding clones in the
presence of control mouse Ig, the difference is significant at p < 0.001 by stu-
dent's t test.
In the presence of:
Tc1 .8 vs.
VIP
Percent specific
MG C5 vs.
MC-M
lysis of.
PT 31 vs.
PT-M
RN C8 vs.
RN-M
Medium 55 49 66 40
Control mouse Ig 61 51 68 36
I-2 (anti-D/DR) 49 47 65 33
W6-32 (anti-MHC-I) 16' 26" 37' 37
A
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Effector - PT31
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melanoma cells, only the unlabeled autologous melanoma cells showed positive com-
petition (Fig. 5). Conversely, against an allogeneic target (FP-M), which was lysed
quite well by A15, no competition between the relevant autologous melanoma cells
and the allogeneic targets, or between the irrelevant allogeneic targets, was noted
(Fig. 5). Since these results could be explained on the basis of possible contamina-
tion of other "nonspecific" populations of cytotoxic cells, clone A15 was recloned.
Unfortunately, our initial attempt to reclone A15 was unsuccessful.
Modulation of Cytotoxic Activities of the CTL Clones.
￿
The cytotoxic activities of all
three clones against the autologous targets could not be modulated at the effector
phase by autologous sera and autologous unactivated PBL (Table II). Thecytotoxic
activities ofthe CTL clones against thecorresponding autologous targets in the MC
and PT systems were blocked by anti-CD3 mAb (data not shown). In contrast, the
cytotoxicity of the Tc1.8 (VIP system) was enhanced significantly by the anti-CD3
treatment. A more detailed analysis of anti-CD3-mediated enhancementofthe cyto-
toxicfunction ofCTLcloneTcl.8 hasbeen communicated earlier (15). Further, with
reference to the restricted and broad target range of the CTL clones PT31 and A15,
the rolesof lymphocyte function-associated (LFA) antigen 1 and intercellular adhe-
sion molecule (ICAM)-1 were examined. Table III shows that while the cytotoxic
activities by A15 against the allogeneic targets were abrogated by anti-LFA-1 and
anti-ICAM-1 antibodies, the same antibodies failed to block the cytotoxicity ofA15
TABLE II
Effect ofAutologous Sera and Autologous Fresh PBL on Cytotoxicity
Percent specific lysis at E/T ratio is 20:1 .
FIGURE 5.
￿
Cold target inhibi-
tion assays with CTLcloneA15
(inthePT system) tested against
the labeled autologous mela-
noma cells PTIM (A) and
against the labeled allogeneic
melanoma cells FP-M cells (B)
in thepresence ofunlabeledPT
Mcells ("), ofunlabeledK-562
cells (O), of unlabeled GB-M
cells (/), ofunlabeledCLB-M
cells(A), andof unlabeledFP-
M cells (*)
In the presence of.
Tc1,8 vs.
VIP
Percent specific lysis of:
MC C5 vs.
MC-M
PT 31 vs.
PT-M
Medium 36 46 52
AB' normal serum 38 52 57
Autologous serum 33 43 44
Autologous PBL 34 47 54TABLE III
Effect of Anti-LFA-1 and Anti-ICAM-1 on Restricted and
"Promiscuous" Cytotoxicity by CTL Clones
Percent specific lysis (E/T ratio is 20:1) is by CTL A15. Percent specific lysis
values shown in parentheses were by the CTL clone PT 31 .
andPT31 against the autologous melanoma cells PTIM (mAbs anti-LFA-1 andanti-
ICAM-1 are gifts of Timothy Springer, Harvard Medical School, Boston, MA).
AntigenDependence, LifeSpan, andStabilityoftheCTL Clones. The CTL clones were
restimulated every 1-3 wk with irradiated autologous melanoma cells (CTL/mela-
noma = 100:1) and, whenever available, with irradiated autologous PBL or with
spleen cells in the PT system. This patient underwent splenectomy, which allowed
us to freeze multiple vials of freshly isolated splenocytes. Despite repeated restimu-
lation, the life span of all three CTL clones in continuous culture varied from 2 to
6 mo. At the end of their life span, the clones entered into "crises" leading to almost
abrupt death. Restimulation at the crisis stage or the addition of higher dosages of
IL-2, rIL-2, or rIL-4 seldom resurrected them.
Regulation ofCytotoxic Effector Response by T Cell Clones andLines.
￿
The evidence for
autologous tumor-specific downregulation of inductionofcytotoxic response in au-
tologous melanoma (10, 11) and in malignant paraganglioma (a tumor of neuroec-
todermal origin [13]) has been published earlier. These studies were continued in
order to further explore T cell-mediated regulation of cytotoxic responses in other
systems. Fig. 6 shows three experimentsin three separate systems in which the cyto-
toxic responses by the autologous PBL were regulated by three respective autolo-
gous CD4* T cell clones exhibiting CD3+, CD4+, and CD8- phenotypes. In the
System MC
￿
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￿
System TF
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FIGURE 6.
￿
Effect of regulatory T cell clones
on cytotoxic responses in three separate au-
tologous systems. In theMC system theeffect
ofclone15 is shownin coculture with MC PBL
and with MC-M melanoma cells in the ab-
sence of exogenous IL-2. In the PJ and TF
systems, the effects of clones I-10 and TF14
are shown in cocultures with the corre-
sponding autologous PBLandmelanoma cells
in the standard in vitro activation coculture
containing exogenous IL-2. Percent specific
lysis at effector/target of 20:1 in the absence
of any regulatory cells (0) and in the pres-
ence ofregulatory cells at PBL/regulatory cells
of 1:1 (®), of3:1 (®), andof 10:1 (®). (/)
Percent specific lysis by the respective regula-
tory cells themselves.
In the presence of:
Percent
PT-M
specific lysis
FP-m
of targets
TF-M
Medium 23 (42) 27 17
Anti-LFA-la 13 (37) 24 8
Anti-LFA-1/3 23 (41) 9 3
Anti-ICAM-1 27 (48) 11 4
Control mouse Ig 26 (43) 37 181968 CYTOTOXIC AND REGULATORY T CELL RESPONSES IN MELANOMA
MC system, the CD4+ autologous clone, 15, upregulated the cytotoxic response.
15 was not cytotoxic against the autologous melanoma cells MC-M . In the other
two systems (PJ and TF), the cytotoxic responses, regardless ofthe magnitudes of
cytotoxicity, were markedly downregulated by the respective CD4+ T cell clones .
In all three systems, the regulation by the T cell clones was observed in a dose-
dependent manner.
The amplification of cytotoxic response in the PBL induced by CD4+ T cell
clones was observed intwoother systems (systems DM andJC). In all three systems
(MC, DM, and JC) the T cell clones exhibited the phenotype of "helper-inducer"
cells (MY, CD4+, CD8-, 4114+, and 2H4-), and they amplified cytotoxicity in
the PBL in IVC with the autologous melanoma cells in the absence of any exoge-
nous IL-2 (Fig. 6 and Table IV). Table IV also shows that the amplification ofcyto-
toxicity by the helper cell clones in the DM and JC systems could be blocked par-
tially by anti-IL-2 antibody or by anti-IFN-y antibody.
Table V shows examples ofdownregulation of cytotoxic responses in three sepa-
rate systems and illustrates three specificity patterns ofdownregulation. In the MM
system, the cytotoxic response by the PBL was signficantly suppressed by a CD4+
clone, MMT4. Thesuppression, however, wasunrestrictedas thecytotoxicresponses
against both the autologous and allogeneic targets (D/DR antigen-positive as well
asD/DR antigen-negative) were suppressed. Asimilar patternofnonrestricted down-
regulation ofcytotoxic response was observed in the CLB system in which a CD4+
T cellline, CLB Ts4 (expanded from a well seeded with 100cellsthat grew vigorously
in continuous culture for>2 mo), completely suppressed the induction ofcytotoxic
response by the autologous PBL against theautologous melanoma cells CLB-M and
another allogeneic melanoma cellline. CLB Ts4did not suppress cytotoxic response
against a third melanoma cell line, PJ-M. It is noteworthy that the melanoma cells
CLB-M and TFMexpressed abundant D/DR II antigen, while the melanoma cell
line PJ-M did not express any D/DR antigen. Interestingly, CLB Ts4 upregulated
itsTac receptor when stimulated withthe autologous and allogeneic targetsexpressing
D/DR antigens and didnot do sowhen stimulated with the D/DR antigen-negative
target PJ-M (Fig. 7). In both systems, the cytotoxic responses in the in vitro activa-
TABLE IV
Effect of Anti-IL-2 and Anti-IFN-y on Th Cell-induced
Amplification of Cytotoxic Response
* IVC between PBL and respective autologous melanoma cells.
1 CD4* T cell clone DM5 in DM system, A5 in JC system, and 15 in MC sys-
tem. Control Ig was either mouse Ig in MC system or mouse and rabbit Ig
in DM and JC system.
Auto IVC* with:
Percent specific lysis (E/T = 20:1) in systems
DM JC MC
Medium alone 4 4 2
+ Helper ceelll 32 21 31
+ Helper cells + anti-IL-2 9 3 16
+ Helper cells + anti-IFN-.y 8 8 NT
+ Helper cells + control Ig 28 16 27MUKHERJI ET AL.
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tion cultures were quite modest. Even the modest cytotoxic responses were almost
totallysuppressedby the regulatory cells. CLBTs4 were not cytotoxic for the autol-
ogous melanoma cells nor for several other melanoma targets (data not shown).
In another melanoma system (GB), the CD4+ clone, GB 1.7, in contrast to the
nonrestricteddownregulation shownbythe clones discussed earlier, downregulated
the induction of cytotoxic response in a more restricted manner. The induction of
cytotoxic response against allogeneic targets was minimally suppressed against one
target and was not suppressed against the other (Table V). In addition, coculture
between GB PBL and GB 1.7 in the presence ofthe allogeneic target PTM (D/DR
antigen-positive) or against PJ-M (D/DR antigen-negative) led to no suppression,
oronlymarginal suppression, ofcytotoxic response against the respective allogeneic
targets (Table V).
Table VI shows an analysis ofthe characteristics ofthe 15 cases in which we were
able to undertake a detailed functional analysis of such Tcell responses. Interest-
ingly, all the CTL clones in this study were CD8+; and all the regulatory clones
exhibiting downregulation ofCTL responses were CD4+. An analysis ofthe mag-
nitude ofcytotoxic response by the activated PBL at population level (at the height
of cytotoxic response, i.e., at 2 wk after initiation of the IVCs) and of the nature
of the clonal responses revealed an interesting correlation. While CTL responses
at clonal levels correlated with substantial cytotoxic responses bythe corresponding
activatedPBL, the emergence ofdownregulatory responseswas associated withvery
lowcytotoxicresponsesbythe correspondingactivatedPBLpopulations (Table VI).
In this analysis, the cytotoxicity values at 2 wk after the initiation ofIVC were used
for calculation of LU.
TABLE V
Specificity Pattern of Downregulation by Cloned T Cell Lines
' Percent suppression or enhancement were calculated from percent specific lysis values at E/T
= 20:1 . Percent lysis by the auto-sensitized BL were 26% against CLB-M, 24% against
MM-T, and 33% against GB-M .
I The la' or la-, as shown in parentheses, represent MHC II antigen expression by the mela-
noma cells.
§ The BL/Regulatory Clone ratios in Exp. 1 and 2 were 3 :1, while the ratio in Exp. 3 was 10:1 .
Exp. IVC condition
Percent suppression ( - ) or enhancement ( + )
of cytotoxicity in the PBL against" :
CLB-M (Ia')l PT-M (Ia*) PJ-M (la-)
1 . CLB PBL + Ts4 + CLB-MS -92 -70 -44
CLB PBL + TO + PT-M -82 -62 -50
CLB PBL + Ts4 + PJ-M - 11 - 7 +10
MM-T (Ia-) VIP (la+) PJ-M (la-)
2 . MM PBL + T-4 + MM-T -38 -49 -35
MM PBL + T-4 + VIP -30 -46 - 17
MM PBL + T-4 + PJ-M -25 -27 -31
GB-M (la') PT-M (Ia') PJ-M (la-)
3 . GB PBL + GB 1 .7 + GB-M -45 -16 + 11
GB PBL + GB 1 .7 + PT-M 0 -21 0
GB PBL + GB 1 .7 + PJ-M 0 -2.5 01970 CYTOTOXIC AND REGULATORY T CELL RESPONSES IN MELANOMA
FIGURE 7 .
￿
Tac antigen expression by CLB T4
line . Thoroughly washedCLB T4 cells were in-
cubated in medium (A), with irradiated la- pJ-
M melanoma cells (B), with Ia' allogeneic RN-
M melanoma cells (C), and with Ia' autologous
melanoma cellsCLB-M (D) for 24 h (T4/mela-
noma cells = 10:1) . After incubation, the CLB
T4 cells were phenotyped for Tac expression by
immunofluorescence technique in the FACS .
Discussion
The results described here reaffirm earlier observations onCTL response against
autologous melanoma from our laboratory (1) and other laboratories (2-4, 6, 7) .
In addition to providing considerable credibility forthenotion that true Tcell effector
response can indeed be demonstrated in autologous human melanoma, this study
also supports the concept that cytotoxic effector response against autologous mela-
noma cells is subject to regulation byT cells . Besides providing support for these
concepts, several interesting points have emerged from this study.
First, the T cell clones Tc1.8, MCC5, and PT 31 share characteristics that are
exhibited by most bonafide CTL. All of them expressed restricted specificity; allMUKHERJI ET AL.
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TABLE VI
An Analysis of the 12 Cases from which CTL and
Regulatory Cones were Obtained
* S, specific ; NS, nonspecifiic.
demonstrated MHC class I-restricted function; and they all used their TCR com-
plexes one way or another. mAb to CD3 (a molecule associatedwith the TCR com-
plex and quite possibly involved in signal transduction) blocked the cytotoxic func-
tion in two cases andenhanced cytotoxicity inthe other. It is ofinterest to notethat,
although the cytotoxicity ofTc1.8 was enhanced by the treatment with CD3 mAb,
Tc1.8 needed the full expression ofthe receptor complex for its function, since modu-
lation of the complex completely abrogated such function (15).
Second, the burdensome demands both ofeffort and oftime involved in carrying
out acompletely satisfactory and thorough functional analysis ofhundreds ofemerging
clones in individual systems do not allow a credible estimate of the frequency of
CTL response in patients with advanced disease. It should be noted that, although
we isolated trueCTL clones demonstrating specificity in limited cases only, we were
able to generate cytotoxicresponsesat population levels againstthe autologous mela-
noma cells in IVC in the majority ofthese patients. Even ifthe cytotoxic responses
induced in IVC in the other systems reflected lymphokine-activated killer cell-type
responses and/or NK cell-type responses, it is quite clear that we were not always
successful in selecting true CTL clones in other systems. In this context, it should
be mentioned that in the PT system, the MHC class I-restricted autospecific CTL
clone PT 31 was isolated in our second attempt. In another system (system AS),
although we were able to demonstrate MHC class II-restricted melanoma-specific
CD4+ CTL response at the population level (data not shown), we failed to isolate
an MHC class II-restricted CD4+ CTL clone from a total of60 expanded and well-
studied CD4+ clones from two separate clonings of 2,000 cells. Thus, these types
of technical uncertainties and difficulties in obtaining CTL clones might account
for an observed low CTL frequency in advanced melanoma.
Third, our dataclearlydemonstrate that a CTLclonedemonstratingawide target
No. System
LU1,000/106
activated
PBL
Clone
derived
from:
Phenotype
of clone Function Specificity*
1 VIP 60 LNL CD8 CTL S
2 MC 48 LNL CD8 CTL S
3 PT 72 PBL CD8 CTL S
4 RN 50 PBL CD8 CTL S
5 JC 35 PBL CD4 Helper S
6 MC 48 LNL CD4 Helper ND
7 DM 18 PBL CD4 Helper S
8 pi 61 LNL CD4 Suppressor S
9 RG 13 LNL CD4 Suppressor NS
10 JG 18 PBL CD4 Suppressor NS
11 MM 20 PBL CD4 Suppressor NS
12 TF 22 PBL CD4 Suppressor NS
13 CLB 20 PBL CD4 Suppressor la
14 GB 11 LNL CD4 Suppressor S
15 AS 32 PBL CD4 Suppressor ND1972 CYTOTOXIC AND REGULATORY T CELL RESPONSES IN MELANOMA
range, or "promiscuous" cytotoxic behavior, may also exhibit antigenic specificity.
Although we cannot rule outthe possibility that the CTL clone PT A15 did nothave
another irrelevant population(s) of cytotoxic cells, the cold target competition ex-
periments with A15 and the relevant autologous and irrelevant allogeneic targets
(Fig. 5) clearly ruledout antigenicsimilarities between theautologous and allogeneic
targets. Thus, in reference to cytotoxicity against the irrelevant allogenic targets,
cloneA15 could have been activated throughinteractions of accessory molecules and
their respective ligandson thetarget cells. Hence, the possibility exists that a bonafide
CTL clone canbe activated through alternateactivation pathways (i.e., CD2-LFA-3
or through other homotypic and/or heterotypic adhesion molecules that may also
serve in signal transduction). Indeed, the cytotoxicity against the irrelevant allogeneic
targets by CTL clone A15 could be substantially blocked by mAbs against LFA-1
and ICAM-1, while the cytotoxicity of A15 against the autologous melanoma cells
was notblocked. Similarly, cytotoxicity of PT 31 againstthe autologous PTIM mela-
noma cells also was not blocked by these reagents (Table III).
Fourth, frequent restimulation by the appropriate antigen and/or autologous ac-
cessory cells was not enough to maintain theseclones indefinitely in continuous cul-
ture. A different strategy, namely, the insertion of a different growth factor gene
or a growth factor receptor gene, such as has been accomplished recently by Pierce
et al. (16), or the induction of immortality through infection or transfection by a
suitable retroviral transforming gene, needs to be considered.
Last, it is clear that once the CTL are activated and amplified, their cytotoxic
function cannot be blocked at the effector phase by autologous PBL or by autolo-
gous sera. Sincethe fresh PBL and LNL(from which theCTLclones were obtained)
were not cytotoxic against their respective autologous melanoma cells, even though
a CTL clone(s) could be isolated from its in vitro activated counterparts, one might
argue that the cytotoxic unresponsiveness in the fresh effector population was not
due to "clonal deletion ." Alternatively, such cytotoxic unresponsiveness might have
been a reflection of their numeric insufficiency or of the lack of "help" required for
activation and amplification ofT cell response. It might have resulted also from the
influence of the regulatory apparatus.
In reference to regulation of antitumor CTL response, although the role of "sup-
pressor cell activity" has received considerable attention (17, 18), the authenticity
of the phenomenon has only been established in the animal tumor system (18-28).
Earlier, we presented the evidence of T cell-mediated downregulation of cytotoxic
response in twohuman systems (10, 11, 13). More recently, Cozzolini et a1. (29) also
have presented indirect evidence of suppressor cell activities in proliferative T cell
response in tumors of thehead and neck region. Further, Livingston et al. (30) have
shown cyclophosphamide-sensitive suppressor cell activities in patients with mela-
noma. Clearly, then, the issue of cell-mediated suppression of immune response to
human tumors has assumed more relevance.
From the above perspective, the present study provides several noteworthy points.
First, our data provide additional support for the view that cell-mediated effector
response against autologous human cancer is subject to both up- and downregula-
tion. The upregulation of cytotoxic response in coculture induced by the CD4+
helper or "helper-inducer" clones in the MC, DM, andJC systems (Fig. 6) is similar
to one of our earlier observations (13). It appears that the amplification of cytotoxicMUKHERJI ET AL.
￿
1973
response in the PBL in IVC by the helper cell clones was mediated primarily by
IL-2 and by IFN--y (Table IV). Since these cytokines can influence the behavior of
adiverse group ofimmunocompetentcells (e.g., CTL, LAK, NK, andeffector mac-
rophages), theseTh cells, therefore, canexert abroadrangeofregulatory influences.
It is noteworthy that, in the MC system, we were also able to document a CTL
response (Fig. 3).
Second, the cells participating in downreguaatory activities are predominantly
CD4' T cells. It is unclear, presently, whether these CD4+ regulatory T cells act
as suppressor effector cellsthemselves or act as intermediaries (suppressor inducers).
In an earlier communication (11) we demonstrated that CD4+ T cells can, indeed,
induce a CD8' suppressor effector population.
Third, the regulatory process includes autorestricted as well as nonrestricted in-
terventions. The autorestricted downregulation by the CD4' clone GB 1.7 ofcyto-
toxic immune response in the GB systems is reminiscent ofsimilar autorestricted
downregulations shown earlier in two other autologous human tumor systems (10,
11, 13). Further, the higher level ofdownregulation induced by the T cell clone GB
1.7 against the autologous target was not due to differential expression of D/DR
antigenbetweenthe melanoma cells GB-M andPTM. In fact, theautologous mela-
noma cells GB-M expressed D/DR antigen quantitatively at a lower level than did
the PTM cells (data not shown). Additional evidence for autologous melanoma-
associated specificity of the regulatory T cell clone GB 1.7 has been observed. For
example, the GB 1.7 cells selectively upregulate their Tac receptors when they are
stimulatedby theautologous melanomacells GB-M; andthey proliferatewhenstimu-
lated by the melanoma cells GB-M and exogenous IL-2 (N. G. Chakravorty, and
B. Mukherji, manuscript submitted for publication).
Fourth, it is clear that the nonselective downregulation ofcytotoxic immune re-
sponse by CD4' T cell clones in the melanoma system may represent regulation
resulting from interaction with the D/DR antigen. The interactions between the
PBL and the MHC class II-bearing melanoma cell CLB-M led to a CD4+ T cell
response that profoundly suppressed cytotoxic responses against both the autolo-
gous and allogeneic melanoma targets (Table V). This is analogous to autologous
mixed lymphocyte reaction (AMLR), which mayleadto downregulation ofimmune
response in different assay systems (31, 32). All nonrestricteddownregulations seen
in our study, however, did not represent similar situations as evidenced by the non-
restricted downregulation against D/DR antigen-negative allogeneic target shown
in the MM system (Table V). The D/DR antigen-induced regulation, nevertheless,
is quite intriguing, considering that a significant percentage ofhuman melanomas
constitutively express D/DR antigens (33). D/DR antigens have been shown to play
a regulatory role in T cell proliferative responses against melanoma cells (34, 35).
From an operational point ofview, whatever molecular specificities the regulatory
cells recognize ("tumor antigen," D/DR antigen, or some other specificity), when
such recognition leads to suppression ofCTL response, the phenomenon assumes
considerable significance in the context ofimmune response to human melanoma.
Interestingly, in this group of patients the emergence of a regulatory response in
our in vitro cocultures was associated with only a modest cytotoxic response in the
effector populations (Table VI).
Finally, it is ofinterest that, in our group ofpatients, identical in vitro activation1974 CYTOTOXIC AND REGULATORY T CELL RESPONSES IN MELANOMA
techniques led to the CTL responses, in some, and regulatory responses (specific
or nonspecific), in others, without any discernable correlation with GD3, GM2, or
D/DR antigen expression by the respective melanoma cells (cumulative data not
shown). Circumstances leading to these two opposite results (CTL vs. regulatory
response) remain unclear. In this context, it should benotedthat immune responses
in the chemically induced tumor system in animals have been known to go through
sequential expression of CTL responses followed by the emergence of regulatory
responses (18, 26). Careful analysis ofimmune responses in patients with primary
melanomas and sequential analysis ofimmune responses in a group ofpatients over
a length of time will provide much insight into this issue.
Summary
T cell-mediated immune response against autologous melanoma cells was ana-
lyzed, at population and clonal levels, in 31 patientswith recurrentand/or metastatic
disease. Fresh PBL and lymph node lymphocytes (LNL) from melanoma-involved
nodes were not cytotoxic against the respective melanoma cells. When activated in
in vitro coculture (IVC) against the autologous melanoma cells in the presence of
IL-2, amajority ofthe activated PBL and LNLbecamecytotoxicagainst theautolo-
gous targets. The activated effector cells were cloned in limiting dilution microcul-
tures, andgrowing clones were phenotypically defined and were functionallycharac-
terized for cytotoxicity and for potential regulatory function.
Functional T cell clones were obtained from 15 of 31 cases. Of these, CTL re-
sponses exhibitingcytotoxicity restricted against the autologous melanoma were seen
in four cases. All four CTL clones were CD3', CD8+, and CD4`. Three ofthese
four CTL clones were studied extensively. All three ofthese CTL clones expressed
MHC class I-restricted cytotoxicity. mAb anti-CD3 blocked cytotoxicity intwo and
enhancedcytotoxicityin the other. Neitherautologous seranor autologous nonacti-
vated freshPBL modulated the cytotoxic functions ofthe CTL clones at the effector
phase. T cell lines exhibiting regulatory function were obtained in 11 cases. The
regulatory T cell lines were CD3+, CD4+, and CD8-. In three cases CD4+ clones
amplified the cytotoxic response in the PBL in coculture, while in eight other cases
the Tcell lines downregulated the cytotoxic responses. Such T cell-mediated down-
regulations were either restricted to the autologous system, induced by D/DR an-
tigens expressedbythe autologous orallogeneic melanomacells, or induced bystimulus
other than D/DR antigens. Taken together, these findings clearly demonstrate the
existence of T cell-mediated cytotoxic and regulatory responses against human
melanoma.
We thank Ms. Joyce M. Fritz for preparation ofthe manuscript.
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